LIVIVO - Search results -

Search results

Result 1 - 10 of total 17017

Search options

Article ; Online: Yi-qi-hua-yu-jie-du decoction induces ferroptosis in cisplatin-resistant gastric cancer via the AKT/GSK3β/NRF2/GPX4 axis.

Huang, Wenjie / Wen, Fang / Yang, Peipei / Li, Ye / Li, Qiurong / Shu, Peng

Phytomedicine : international journal of phytotherapy and phytopharmacology

2023 Volume 123, Page(s) 155220

Abstract: ... for its treatment. Yi-qi-hua-yu-jie-du decoction (YJD), an empirical formula in Traditional Chinese Medicine (TCM ...

Abstract	Background: Resistance to chemotherapy in gastric cancer (GC) is a ubiquitous challenge for its treatment. Yi-qi-hua-yu-jie-du decoction (YJD), an empirical formula in Traditional Chinese Medicine (TCM), demonstrated survival-prolonging functions in patients with GC. Previous research has shown that YJD could also inhibit drug resistance in GC. However, the precise mechanisms for how YJD accomplishes this remain incompletely explained. Purpose: The research aimed to identify differential metabolic characteristics in cisplatin-resistant GC and investigate whether YJD can target these differences to suppress GC drug resistance. Methods: Metabolomic analysis was conducted to identify metabolic disparities between cisplatin-resistant and parental GC cells, as well as metabolic modifications resulting from YJD intervention in cisplatin-resistant GC cells. The effect of YJD on ferroptosis stimulation was assessed by measuring the levels of reactive oxygen species (ROS), malondialdehyde (MDA), iron ions, the reduced glutathione (GSH) to oxidised glutathione (GSSG) ratio, and alterations in mitochondrial morphology. Western blotting and quantitative real-time polymerase chain reaction (Q-PCR) were employed to verity the mechanisms of YJD-triggered ferroptosis through GPX4 and NRF2 overexpression models, alongside the AKT activator SC79. In vivo validation was conducted using nude mouse xenograft models. Results: Cisplatin-resistant GC exhibited altered GSH/GPX4 metabolism, and ferroptosis was a significantly enriched cell death pattern with YJD treatment in cisplatin-resistant GC cells. Ferroptosis biomarkers, including ROS, MDA, iron ions, the GSH/GSSG ratio, and mitochondrial morphology, were remarkably changed with the YJD intervention. Mechanistic experiments demonstrated that YJD inhibited the phosphorylation cascade activity of the AKT/GSK3β pathway, thereby reducing NRF2 expression. The level of GPX4, a crucial enzyme involved in glutathione metabolism, was attenuated, facilitating ferroptosis induction in cisplatin-resistant GC. Conclusion: The research reveals, for the first time, changes in GSH/GPX4 metabolism in cisplatin-resistant GC cells based on metabolomic analysis. YJD induced ferroptosis in cisplatin-resistant GC by inhibiting GPX4 through the AKT/GSK3β/NRF2 pathway, thus attenuating the cisplatin drug resistance in GC. Our findings identify metabolic changes in cisplatin-resistant GC and establish a theoretical framework for YJD on tackling drug resistance in GC through ferroptosis.
MeSH term(s)	Animals ; Mice ; Humans ; Cisplatin/pharmacology ; Stomach Neoplasms/drug therapy ; Glycogen Synthase Kinase 3 beta ; NF-E2-Related Factor 2 ; Proto-Oncogene Proteins c-akt ; Ferroptosis ; Glutathione Disulfide ; Reactive Oxygen Species ; Ions ; Iron
Chemical Substances	Cisplatin (Q20Q21Q62J) ; Glycogen Synthase Kinase 3 beta (EC 2.7.11.1) ; NF-E2-Related Factor 2 ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Glutathione Disulfide (ULW86O013H) ; Reactive Oxygen Species ; Ions ; Iron (E1UOL152H7)
Language	English
Publishing date	2023-11-18
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1205240-1
ISSN	1618-095X ; 0944-7113
ISSN (online)	1618-095X
ISSN	0944-7113
DOI	10.1016/j.phymed.2023.155220
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4115: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sheng-ji Hua-yu ointment ameliorates cutaneous wound healing in diabetes via up-regulating CCN1.

Yang, Dan / Tan, Yi-Mei / Zhang, Ying / Song, Jian-Kun / Luo, Yue / Luo, Ying / Fei, Xiao-Ya / Ru, Yi / Li, Bin / Jiang, Jing-Si / Kuai, Le

Journal of ethnopharmacology

2022 Volume 303, Page(s) 115954

Abstract: ... of diabetes, and efficacious therapeutic means are currently lacking. Sheng-ji Hua-yu (SJHY) ointment is ...

Abstract	Ethnopharmacological relevance: Diabetic ulcers (DUs) are one of the most severe complications of diabetes, and efficacious therapeutic means are currently lacking. Sheng-ji Hua-yu (SJHY) ointment is a classical Chinese traditional prescription that can significantly attenuate DU defects, but the specific mechanism remains to be fully elucidated. Aim of the study: In order to verify the underlying mechanism of SJHY ointment in accelerating the closure of DUs. Materials and methods: Modular pharmacology and molecular docking were utilized to predict the therapeutic targets of SJHY ointment against DUs. Male db/db diabetic mice and HaCaT cell models induced by methylglyoxal were used to validate the findings. Results: CCN1 was proven to be the core target of SJHY ointment involved in DUs treatment. CCN1 up-regulated by SJHY treatment (0.5 g/cm Conclusions: SJHY ointment ameliorates cutaneous wound healing by up-regulating CCN1.
Language	English
Publishing date	2022-11-24
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	134511-4
ISSN	1872-7573 ; 0378-8741
ISSN (online)	1872-7573
ISSN	0378-8741
DOI	10.1016/j.jep.2022.115954
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Identification of the Biomarkers of Sheng-Ji Hua-Yu Formula Treated Diabetic Wound Healing Using Modular Pharmacology.

Jiang, Jing-Si / Zhang, Ying / Luo, Ying / Ru, Yi / Luo, Yue / Fei, Xiao-Ya / Song, Jian-Kun / Ding, Xiao-Jie / Zhang, Zhan / Yang, Dan / Yin, Shuang-Yi / Zhang, Hui-Ping / Liu, Tai-Yi / Li, Bin / Kuai, Le

Frontiers in pharmacology

2021 Volume 12, Page(s) 726158

Abstract: Sheng-Ji Hua-Yu (SJHY) formula has been proved to reduce the severity of diabetic wound healing ...

Abstract	Sheng-Ji Hua-Yu (SJHY) formula has been proved to reduce the severity of diabetic wound healing without significant adverse events in our previous clinical trials. However, based on multi-target characteristics, the regulatory network among herbs, ingredients, and hub genes remains to be elucidated. The current study aims to identify the biomarkers of the SJHY formula for the treatment of diabetic wound healing. First, a network of components and targets for the SJHY formula was constructed using network pharmacology. Second, the ClusterONE algorithm was used to build a modular network and identify hub genes along with kernel pathways. Third, we verified the kernel targets by molecular docking to select hub genes. In addition, the biomarkers of the SJHY formula were validated by animal experiments in a diabetic wound healing mice model. The results revealed that the SJHY formula downregulated the mRNA expression of
Language	English
Publishing date	2021-11-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2021.726158
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Clinical observation of Dan-Hong Hua-Yu oral solution in treating retinal vein occlusion.

Li, Tie-Jun / Sun, Yu-Chen / Ma, Qiu-Yan / Wu, Yan / Yang, Chao / Zhang, Nan / Yang, Yue / Yang, Ying-Xin

Medicine

2020 Volume 99, Issue 21, Page(s) e20173

Abstract: ... the efficacy of Dan-Hong Hua-Yu oral solution in treating non-ischemic retinal vein occlusion, in order ... into a treatment group and a control group. The intervention group will be treated with Dan-Hong Hua-Yu oral ... the efficacy of Dan-Hong Hua-Yu oral solution in the treatment of non-ischemic central retinal vein occlusion ...

Abstract	Introduction: Retinal vein occlusion refers to diseases with decreased vision, dilated tortuous retinal veins visible on the fundus, and retinal hemorrhage, edema, and osmosis distributed along the vein. There is still no ideal intervention to treat central retinal vein occlusion. This study plan to observe the efficacy of Dan-Hong Hua-Yu oral solution in treating non-ischemic retinal vein occlusion, in order to provide new treatment ideas. Methods/design: We plan to use random number table method, 64 cases of non-ischemic central retinal vein occlusion that meet the inclusion criteria will be randomly divided into a treatment group and a control group. The intervention group will be treated with Dan-Hong Hua-Yu oral solution according to the syndrome differentiation of Traditional Chinese medicine and the patient's fundus condition. Each group will take 4 weeks as a course of treatment and three consecutive courses of treatment without any interval during the course of treatment. Changes of visual acuity, fundus performance, and total clinical symptoms of patients before and after treatment will be observed. Discussion: This study will observe the efficacy of Dan-Hong Hua-Yu oral solution in the treatment of non-ischemic central retinal vein occlusion, with a view to providing new treatment ideas. Trial registration: ClinicalTrials.gov, ChiCTR2000030625, Registered on March 08, 2020.
MeSH term(s)	Administration, Oral ; Adult ; Aged ; Case-Control Studies ; China/epidemiology ; Drugs, Chinese Herbal/administration & dosage ; Drugs, Chinese Herbal/therapeutic use ; Female ; Fluorescein Angiography/methods ; Fundus Oculi ; Humans ; Macular Edema/diagnostic imaging ; Macular Edema/drug therapy ; Macular Edema/pathology ; Male ; Middle Aged ; Retinal Vein Occlusion/diagnostic imaging ; Retinal Vein Occlusion/drug therapy ; Retinal Vein Occlusion/pathology ; Visual Acuity/drug effects
Chemical Substances	Drugs, Chinese Herbal ; danhong huayu koufuye
Language	English
Publishing date	2020-06-01
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Randomized Controlled Trial
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000020173
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Gene set enrichment analysis and ingenuity pathway analysis to identify biomarkers in Sheng-ji Hua-yu formula treated diabetic ulcers.

Ru, Yi / Zhang, Ying / Xiang, Yan-Wei / Luo, Ying / Luo, Yue / Jiang, Jing-Si / Song, Jian-Kun / Fei, Xiao-Ya / Yang, Dan / Zhang, Zhan / Zhang, Hui-Ping / Liu, Tai-Yi / Yin, Shuang-Yi / Li, Bin / Kuai, Le

Journal of ethnopharmacology

2021 Volume 285, Page(s) 114845

Abstract: Ethnopharmacological relevance: Sheng-ji Hua-yu (SJHY) formula is a Chinese herbal prescription ...

Abstract	Ethnopharmacological relevance: Sheng-ji Hua-yu (SJHY) formula is a Chinese herbal prescription for diabetic ulcers (DUs) treatment, which can accelerate wound reconstruction and shorten the healing time. However, its mechanism role maintains unclear. Aim of the study: To elucidate the molecular mechanisms of SJHY application on DUs. Materials and methods: To begin with, transcriptome sequencing was adopted to identified differentially expression mRNAs among normal ulcers, DUs, and DUs + SJHY treatment in vivo. Liquid chromatography-tandem mass spectrometry was applied for the quality control of SJHY formula. GO and KEGG enrichment analysis were used to identify the mechanisms underlying the therapeutic effect of SJHY formula, and then gene set enrichment analysis and ingenuity pathway analysis were conducted for functional analysis. Further, qPCR detection was performed in vivo for validation. Results: SJHY administration could regulate the glucose metabolic process, AMPK and HIF-1 pathway to accelerate healing processes of DUs. Besides, CRHR1, SHH, and GAL were identified as the critical targets, and SLC6A3, GRP, FGF23, and CYP27B1 were considered as the upstream genes of SJHY treatment. Combined with animal experiments, the prediction results were validated in DUs mice model. Conclusions: This study used modular pharmacology analysis to identify the biomarkers of SJHY formula and provide the potential therapeutic targets for DUs treatment as well.
MeSH term(s)	Animals ; Humans ; Mice ; Diabetes Complications ; Diabetes Mellitus, Experimental ; Drugs, Chinese Herbal/therapeutic use ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Skin Ulcer/drug therapy ; Skin Ulcer/etiology ; Wound Healing/drug effects
Chemical Substances	Drugs, Chinese Herbal ; RNA, Messenger ; Sheng-ji Hua-yu
Language	English
Publishing date	2021-11-17
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	134511-4
ISSN	1872-7573 ; 0378-8741
ISSN (online)	1872-7573
ISSN	0378-8741
DOI	10.1016/j.jep.2021.114845
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Gene set enrichment analysis and ingenuity pathway analysis to identify biomarkers in Sheng-ji Hua-yu formula treated diabetic ulcers

Ru, Yi / Zhang, Ying / Xiang, Yan-wei / Luo, Ying / Luo, Yue / Jiang, Jing-si / Song, Jian-kun / Fei, Xiao-ya / Yang, Dan / Zhang, Zhan / Zhang, Hui-ping / Liu, Tai-yi / Yin, Shuang-yi / Li, Bin / Kuai, Le

Journal of ethnopharmacology. 2022 Mar. 01, v. 285

2022

Abstract: Sheng-ji Hua-yu (SJHY) formula is a Chinese herbal prescription for diabetic ulcers (DUs) treatment ...

Abstract	Sheng-ji Hua-yu (SJHY) formula is a Chinese herbal prescription for diabetic ulcers (DUs) treatment, which can accelerate wound reconstruction and shorten the healing time. However, its mechanism role maintains unclear.To elucidate the molecular mechanisms of SJHY application on DUs.To begin with, transcriptome sequencing was adopted to identified differentially expression mRNAs among normal ulcers, DUs, and DUs + SJHY treatment in vivo. Liquid chromatography-tandem mass spectrometry was applied for the quality control of SJHY formula. GO and KEGG enrichment analysis were used to identify the mechanisms underlying the therapeutic effect of SJHY formula, and then gene set enrichment analysis and ingenuity pathway analysis were conducted for functional analysis. Further, qPCR detection was performed in vivo for validation.SJHY administration could regulate the glucose metabolic process, AMPK and HIF-1 pathway to accelerate healing processes of DUs. Besides, CRHR1, SHH, and GAL were identified as the critical targets, and SLC6A3, GRP, FGF23, and CYP27B1 were considered as the upstream genes of SJHY treatment. Combined with animal experiments, the prediction results were validated in DUs mice model.This study used modular pharmacology analysis to identify the biomarkers of SJHY formula and provide the potential therapeutic targets for DUs treatment as well.
Keywords	biomarkers ; genes ; glucose ; liquid chromatography ; pharmacology ; prediction ; quality control ; tandem mass spectrometry ; therapeutics ; traditional medicine ; transcriptome
Language	English
Dates of publication	2022-0301
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	134511-4
ISSN	1872-7573 ; 0378-8741
ISSN (online)	1872-7573
ISSN	0378-8741
DOI	10.1016/j.jep.2021.114845
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 90/710: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hua-Zhuo-Kai-Yu decoction inhibits apoptosis in nonalcoholic fatty liver disease

Yu-Ting Li / Huan-Tian Cui / Lu Yang / Lu-Lu Jin / Yu-Ming Wang / Xue-Qian Dong / Wei-Bo Wen / Hong-Wu Wang / Zhai-Yi Zhang

Traditional Medicine Research, Vol 6, Iss 1, Pp 5-

2021 Volume 5

Abstract: Background: Hua-Zhuo-Kai-Yu decoction (HZKY) is an empirical formula ...

Abstract	Background: Hua-Zhuo-Kai-Yu decoction (HZKY) is an empirical formula in traditional Chinese medicine that is derived from the classic ancient prescription Da-Chai-Hu decoction. It has been demonstrated to have good clinical effects on nonalcoholic fatty liver disease (NAFLD). However, the mechanism by which HZKY acts on NAFLD remains unclear. In this study, network pharmacology was used to predict the potential targets of HZKY in NAFLD. Additionally, in vivo studies were conducted to validate the crucial pathways determined using network pharmacology. Methods: Active compounds in HZKY were screened using the Traditional Chinese Medicine Systems Pharmacology and Analysis Platform and Traditional Chinese Medicine Integrated Database, and the potential targets of compounds in HZKY were predicted using Traditional Chinese Medicine Systems Pharmacology and Analysis Platform, Traditional Chinese Medicine Integrated Database, Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine, and PUBCHEM. In addition, targets involved in NAFLD were obtained from the GeneCards and Online Mendelian Inheritance in Man databases, and the potential targets of HZKY in NAFLD were identified based on the common potential targets between HZKY and NAFLD. Cytoscape 3.7.2 was used to visualize crosstalk and identify the key genes from the potential targets of HZKY in NAFLD. Kyoto Encyclopedia of Genes and Genomes analysis was conducted to predict the pathways by which HZKY acts on NAFLD. Rats were fed with a high-fat diet for 12 weeks to induce NAFLD and were then orally administered HZKY. Serum lipid levels and hematoxylin and eosin and oil red O staining results were assessed to determine the effects of HZKY in NALFD. Furthermore, the mechanisms of action of HZKY in NAFLD, as determined using network pharmacology, were validated based on the inhibition of apoptosis in the liver using Western blotting. Results: A total of 269 potential targets of 130 active compounds in HZKY were identified (oral bioavailability ≥ 30% and drug-like ≥ 0.18), and 62 targets were selected after being compared with the targets of NAFLD. Bcl-2-associated X protein (BAX), caspase3 (CASP3), and caspase9 (CASP9) were the key genes with the highest values of network connectivity. In addition, 45 Kyoto Encyclopedia of Genes and Genomes pathways, including apoptosis, fatty acid synthesis, and estrogen signaling, were enriched according to the selected genes of HZKY. In vivo studies showed that the serum levels of total cholesterol, triglyceride, and low-density lipoprotein cholesterol were significantly elevated and the serum level of high-density lipoprotein cholesterol was decreased in the model group compared with those in the control group (P < 0.01 for all). The expressions of BAX, CASP9, and CASP3 were upregulated in the model group compared with those in the control group (P < 0.05, P < 0.01, and P < 0.01, respectively), while HZKY treatment decreased the body weights and serum levels of total cholesterol, triglyceride, and low-density lipoprotein cholesterol and increased the serum levels of high-density lipoprotein cholesterol in NAFLD model rats (P < 0.05, P < 0.01, P < 0.05, and P < 0.05, respectively). Hematoxylin and eosin and oil red O staining indicated that HZKY treatment reduced steatosis in the hepatocytes. Moreover, HZKY treatment inhibited apoptosis in the liver by downregulating the expressions of BAX, CASP3, and CASP9 (P < 0.05, P < 0.01, and P < 0.05, respectively). Conclusion: Our study demonstrates that HZKY improves NAFLD by inhibiting apoptosis in the liver by reducing the levels of BAX, CASP3, and CASP9.
Keywords	network pharmacology ; hua-zhuo-kai-yu decoction ; nonalcoholic fatty liver disease ; apoptosis ; Medicine ; R ; Miscellaneous systems and treatments ; RZ409.7-999
Subject code	610
Language	English
Publishing date	2021-01-01T00:00:00Z
Publisher	Hong Kong Gold Orchid Science and Technology Co., Limited
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book: Ji hua sheng yu lin chuang shou ce

Han, Hsiang-yang

1988

Title translation	Clinical handbook for planned parenthood.
Author's details	zhu bian Han Xiangyang
MeSH term(s)	Contraception ; Family Planning Services
Language	Chinese
Size	8, 578 p. :, ill.
Edition	Di 1 ban.
Publisher	Ren min wei sheng chu ban she
Publishing place	Beijing Shi
Document type	Book
ISBN	9787117005555 ; 7117005556
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book: Ji hua sheng yu zhi shi wen da

Han, Hsiang-yang

1972

Author's details	Han Xiangyang bian
MeSH term(s)	Family Planning Policy ; Contraception
Keywords	China
Language	Chinese
Size	109 p. :, ill.
Edition	Di 1 ban.
Publisher	Ren min wei sheng chu ban she
Publishing place	Beijing
Document type	Book
Database	Catalogue of the US National Library of Medicine (NLM)

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book: Han hua xiang shi yu Zhong yi wen hua

Yang, Jinping

2010

Author's details	Yang Jinping zhu
MeSH term(s)	Medicine in Art ; Medicine, Chinese Traditional/history ; History, Ancient
Keywords	China
Language	Chinese
Size	12, 194 p. :, ill.
Edition	Di 1 ban.
Publisher	Ren min wei sheng chu ban she
Publishing place	Beijing
Document type	Book
ISBN	9787117128605 ; 7117128607
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED